AU2021444937A1 - Compounds for degrading alpha-synuclein aggregates and uses thereof - Google Patents

Compounds for degrading alpha-synuclein aggregates and uses thereof Download PDF

Info

Publication number
AU2021444937A1
AU2021444937A1 AU2021444937A AU2021444937A AU2021444937A1 AU 2021444937 A1 AU2021444937 A1 AU 2021444937A1 AU 2021444937 A AU2021444937 A AU 2021444937A AU 2021444937 A AU2021444937 A AU 2021444937A AU 2021444937 A1 AU2021444937 A1 AU 2021444937A1
Authority
AU
Australia
Prior art keywords
formula
alkyl
substituted
compound
unsubstituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2021444937A
Other languages
English (en)
Inventor
Ming-Kuei Jang
Yih-Shyan Lin
Paul Tempest
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aprinoia Therapeutics Ltd
Original Assignee
Aprinoia Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aprinoia Therapeutics Ltd filed Critical Aprinoia Therapeutics Ltd
Publication of AU2021444937A1 publication Critical patent/AU2021444937A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/545—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Treating Waste Gases (AREA)
AU2021444937A 2021-05-14 2021-05-14 Compounds for degrading alpha-synuclein aggregates and uses thereof Abandoned AU2021444937A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/IB2021/054167 WO2022238737A1 (en) 2021-05-14 2021-05-14 Compounds for degrading alpha-synuclein aggregates and uses thereof

Publications (1)

Publication Number Publication Date
AU2021444937A1 true AU2021444937A1 (en) 2023-11-30

Family

ID=76034924

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2021444937A Abandoned AU2021444937A1 (en) 2021-05-14 2021-05-14 Compounds for degrading alpha-synuclein aggregates and uses thereof

Country Status (8)

Country Link
EP (1) EP4337259A1 (https=)
JP (1) JP2024517340A (https=)
KR (1) KR20240008335A (https=)
CN (1) CN117377496A (https=)
AU (1) AU2021444937A1 (https=)
CA (1) CA3218573A1 (https=)
TW (1) TW202304516A (https=)
WO (1) WO2022238737A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025162452A1 (zh) * 2024-01-29 2025-08-07 思努赛生物科技(上海)有限责任公司 一种识别α-突触核蛋白聚集体的化合物及其用途
CN118845735A (zh) * 2024-06-21 2024-10-29 合肥综合性国家科学中心大健康研究院 金刚烷衍生物在制备离子通道tmem175激动剂中的应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10300155B2 (en) * 2015-12-31 2019-05-28 Washington University Alpha-synuclein ligands
MX2019005007A (es) 2016-11-01 2019-07-18 Arvinas Inc Protac dirigidos a la proteína tau y métodos asociados de uso.
ES2965049T3 (es) 2017-07-12 2024-04-10 Dana Farber Cancer Inst Inc Compuestos para la degradación de la proteína tau
TW201946624A (zh) 2018-05-09 2019-12-16 新旭生技股份有限公司 雜芳基化合物及其用途
JP7297053B2 (ja) * 2018-08-20 2023-06-23 アルビナス・オペレーションズ・インコーポレイテッド 神経変性疾患を治療するためのｅ３ユビキチンリガーゼ結合活性を有するキメラ（ｐｒｏｔａｃ）化合物を標的とし、アルファ－シヌクレインタンパク質を標的とするタンパク質分解
PH12022500002A1 (en) * 2019-06-28 2023-04-03 Kymera Therapeutics Inc Irak degraders and uses thereof

Also Published As

Publication number Publication date
JP2024517340A (ja) 2024-04-19
CA3218573A1 (en) 2022-11-17
KR20240008335A (ko) 2024-01-18
WO2022238737A1 (en) 2022-11-17
CN117377496A (zh) 2024-01-09
TW202304516A (zh) 2023-02-01
EP4337259A1 (en) 2024-03-20

Similar Documents

Publication Publication Date Title
US11291732B1 (en) Compounds for degrading α-synuclein aggregates and uses thereof
AU2017222958B2 (en) Glycosidase inhibitors
AU2017222964B2 (en) Glycosidase inhibitors
JP6851367B2 (ja) Ｉｒａｋ４阻害剤、及びその応用
AU2019309448B2 (en) Substituted quinazolinone derivatives and their use as positive allosteric modulators of mGluR4
EP3548476A1 (en) Ire1 small molecule inhibitors
EP4090426B1 (en) Substitutes for pyrazolos and pyrimidines and their uses
AU2021444937A1 (en) Compounds for degrading alpha-synuclein aggregates and uses thereof
AU2021262281A1 (en) 1,5-dihydro-2,4-benzodiazepine-3-one derivative and application thereof
TW201113290A (en) Novel fused thiazolo and oxazolo pyrimidinones
AU2020383593B2 (en) Compounds for degrading Tau protein aggregates and uses thereof
JP7836089B2 (ja) 微生物誘導性アミロイドの阻害剤
HK40069557B (zh) 用於降解tau蛋白聚集体的化合物及其用途
HK40080583A (en) 1,5-dihydro-2,4-benzodiazepine-3-one derivative and application thereof
HK40069557A (en) Compounds for degrading tau protein aggregates and uses thereof